Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Lynparza (olaparib)
i
Other names:
AZD 2281, AZD-2281, AZD2281, KU-59436, KU-59436, KU-0059436, MK-7339, MK7339, AZD221
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(342)
News
Trials
Company:
AstraZeneca, Merck (MSD)
Drug class:
PARP inhibitor
Related drugs:
‹
talazoparib (81)
niraparib (80)
rucaparib (71)
ABT-888 (35)
pamiparib (18)
fluzoparib (12)
JPI-547 (7)
IMP4297 (6)
MK-4837 (3)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
E7016 (0)
HWH340 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3000 series (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
talazoparib (81)
niraparib (80)
rucaparib (71)
ABT-888 (35)
pamiparib (18)
fluzoparib (12)
JPI-547 (7)
IMP4297 (6)
MK-4837 (3)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
E7016 (0)
HWH340 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3000 series (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
›
Associations
(342)
News
Trials
VERI cancer hierarchy
Reset Filters
BRCA2 mutation
Pancreatic Cancer
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Pancreatic Cancer
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Fallopian Tube Cancer
HRD
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
BRCA1 mutation
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
ATM mutation
Prostate Cancer
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Breast Cancer
BRCA2 mutation
Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
HR negative + BRCA1 mutation
HER2 Negative Breast Cancer
HR negative + BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
HRD + BRCA2 mutation
Ovarian Cancer
HRD + BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A2 - Guideline
bevacizumab + olaparib
Sensitive
:
A2
bevacizumab + olaparib
Sensitive: A2 - Guideline
bevacizumab + olaparib
Sensitive
:
A2
HRD + BRCA1 mutation
Ovarian Cancer
HRD + BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A2 - Guideline
bevacizumab + olaparib
Sensitive
:
A2
bevacizumab + olaparib
Sensitive: A2 - Guideline
bevacizumab + olaparib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login